Everest medicines announces first patient dosed with evm16, its first internally developed personalized mrna cancer vaccine

The first patient has been dosed with evm16 at peking university cancer hospital, marking a major milestone as everest's proprietary ai-based tumor neoantigen prediction algorithm and clinically validated mrna platform progress into human trials. in preclinical studies, evm16 demonstrated significant tumor growth inhibition in syngeneic mouse model, with repeated dosing showing favorable safety and tolerability.
EG Ratings Summary
EG Quant Ranking